NO20082264L - Histamin-3 reseptorantagonister - Google Patents

Histamin-3 reseptorantagonister

Info

Publication number: NO20082264L
Authority: NO; Norway
Prior art keywords: compound; formula; disorder; disorders; congestion
Prior art date: 2005-10-27

Application number

NO20082264A

Other languages

English (en)

Norwegian (no)

Inventor

Travis T Wager

Ramalakshmi Yegna Chandrasekaran

Todd William Butler

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-27

Filing date

2008-05-16

Publication date

2008-07-22

2008-05-16 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-07-22 Publication of NO20082264L publication Critical patent/NO20082264L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Psychology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20082264A 2005-10-27 2008-05-16 Histamin-3 reseptorantagonister NO20082264L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73099605P	2005-10-27	2005-10-27
PCT/IB2006/002977 WO2007049123A1 (fr)	2005-10-27	2006-10-16	Antagonistes des récepteurs de l'histamine h3

Publications (1)

Publication Number	Publication Date
NO20082264L true NO20082264L (no)	2008-07-22

Family

ID=37776539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20082264A NO20082264L (no)	2005-10-27	2008-05-16	Histamin-3 reseptorantagonister

Country Status (39)

Country	Link
US (2)	US8158673B2 (fr)
EP (1)	EP1951660B1 (fr)
JP (2)	JP4319245B2 (fr)
KR (1)	KR101025358B1 (fr)
CN (1)	CN101296898B (fr)
AP (1)	AP2403A (fr)
AR (1)	AR056879A1 (fr)
AU (1)	AU2006307645B2 (fr)
BR (1)	BRPI0617797A2 (fr)
CA (1)	CA2621323C (fr)
CR (1)	CR9910A (fr)
CU (1)	CU23806B7 (fr)
DK (1)	DK1951660T3 (fr)
DO (1)	DOP2006000239A (fr)
EA (1)	EA013602B1 (fr)
EC (1)	ECSP088373A (fr)
ES (1)	ES2444370T3 (fr)
GE (1)	GEP20104937B (fr)
GT (1)	GT200600471A (fr)
HN (1)	HN2006036385A (fr)
HR (1)	HRP20140061T1 (fr)
IL (1)	IL189866A (fr)
MA (1)	MA29888B1 (fr)
MY (1)	MY145001A (fr)
NI (1)	NI200800132A (fr)
NL (1)	NL1032713C2 (fr)
NO (1)	NO20082264L (fr)
NZ (1)	NZ566488A (fr)
PE (1)	PE20070720A1 (fr)
PL (1)	PL1951660T3 (fr)
PT (1)	PT1951660E (fr)
RS (2)	RS20080173A (fr)
SI (1)	SI1951660T1 (fr)
TN (1)	TNSN08150A1 (fr)
TW (1)	TWI318206B (fr)
UA (1)	UA88719C2 (fr)
UY (1)	UY29882A1 (fr)
WO (1)	WO2007049123A1 (fr)
ZA (1)	ZA200803130B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8158673B2 (en) *	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
SI2124933T1 (sl) *	2007-01-22	2012-12-31	Pfizer Products Inc.	Tosilatna sol terapevtske spojine in farmacevtski sestavi tega
JP5497429B2 (ja)	2007-03-07	2014-05-21	武田薬品工業株式会社	ベンゾオキサゼピン誘導体およびその用途
DK2195293T3 (da)	2007-08-22	2014-02-03	Astrazeneca Ab	Cyclopropylamidderivater
NZ585671A (en) *	2007-12-07	2012-06-29	Pfizer	Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
US8691804B2 (en)	2008-05-08	2014-04-08	Evotec Ag	Azetidines and cyclobutanes as histamine H3 receptor antagonists
TW201039825A (en)	2009-02-20	2010-11-16	Astrazeneca Ab	Cyclopropyl amide derivatives 983
CA2788444A1 (fr)	2010-02-18	2011-08-25	Astrazeneca Ab	Nouvelle forme cristalline d'un derive cyclopropyl-benzamide
CA2830027C (fr)	2011-03-31	2016-04-26	Pfizer Inc.	Nouvelles pyridones bicycliques
WO2012172449A1 (fr)	2011-06-13	2012-12-20	Pfizer Inc.	Lactames convenant comme inhibiteurs des bêta-sécrétases
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013151982A1 (fr)	2012-04-03	2013-10-10	Arena Pharmaceuticals, Inc.	Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
EP2852597B1 (fr)	2012-05-04	2016-06-08	Pfizer Inc	Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
NZ702571A (en)	2012-06-29	2017-02-24	Pfizer	4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014045162A1 (fr)	2012-09-20	2014-03-27	Pfizer Inc.	Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
EP2919788A4 (fr)	2012-11-14	2016-05-25	Univ Johns Hopkins	Méthodes et compositions pour le traitement de la schizophrénie
CA2893256A1 (fr)	2012-12-11	2014-06-19	Pfizer Inc.	Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
CA2893333C (fr)	2012-12-19	2017-10-24	Pfizer Inc.	Composes hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitues carbocycliques et heterocycliques
EP2956458B1 (fr)	2013-02-13	2017-08-09	Pfizer Inc	Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2958915B1 (fr)	2013-02-19	2017-07-05	Pfizer Inc	Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
ES2742078T3 (es)	2013-10-04	2020-02-13	Pfizer	Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
WO2015092592A1 (fr)	2013-12-17	2015-06-25	Pfizer Inc.	Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
MX369074B (es)	2014-04-01	2019-10-28	Pfizer	Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa.
JP6111002B1 (ja)	2014-04-10	2017-04-05	ファイザー・インク	２−アミノ−６−メチル−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル−１，３−チアゾール−４−イルアミド
WO2016012896A1 (fr)	2014-07-24	2016-01-28	Pfizer Inc.	Composés de pyrazolopyrimidine
AU2015298378B2 (en)	2014-08-06	2018-08-02	Pfizer Inc.	Imidazopyridazine compounds
EA033423B1 (ru)	2015-02-03	2019-10-31	Pfizer	Циклопропанбензофуранилпиридопиразиндионы
EP3766885B1 (fr)	2015-06-17	2022-05-25	Pfizer Inc.	Composés tricycliques comme inhibiteurs de la phosphodiesterase
RU2722149C1 (ru)	2015-09-14	2020-05-27	Пфайзер Инк.	Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051276A1 (fr)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
WO2017051294A1 (fr)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
WO2017145013A1 (fr)	2016-02-23	2017-08-31	Pfizer Inc.	Composés 6,7-dihydro-5 h-pyrazolo [5,1-b] [1,3]oxazine-2-carboxamide
ES2878160T3 (es)	2016-07-01	2021-11-18	Pfizer	Derivados de 5,7-dihidro-pirrolo-piridina para el tratamiento de enfermedades neurológicas y neurodegenerativas
IL269215B (en)	2017-03-10	2022-09-01	Pfizer	Disubstituted imidazole[4,5-c]quinoline derivatives
BR112019018688A2 (pt)	2017-03-10	2020-04-07	Pfizer	derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
CA3066077A1 (fr)	2017-06-07	2018-12-13	Adrx, Inc.	Inhibiteur d'agregation de tau
SG11201913014YA (en)	2017-06-22	2020-01-30	Pfizer	Dihydro-pyrrolo-pyridine derivatives
EP3668886A2 (fr)	2017-08-18	2020-06-24	Adrx, Inc.	Inhibiteurs peptidiques d'agrégation de tau
PL3768669T3 (pl)	2018-03-23	2023-07-03	Pfizer Inc.	Pochodne azaspiro piperazyny
US12144815B2 (en)	2021-02-23	2024-11-19	Hoth Therapeutics, Inc.	Use of aprepitant for treating Alzheimer's disease
CN116514645A (zh) *	2023-04-08	2023-08-01	绍兴上虞华伦化工有限公司	二氟-4溴苯甲醛及其制备工艺
WO2025145091A1 (fr)	2023-12-29	2025-07-03	Pfizer Inc.	Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6559140B2 (en) *	2000-03-09	2003-05-06	Abbott Laboratories	Cyclic and bicyclic diamino histamine-3 receptor antagonists
CA2441080A1 (fr)	2001-03-23	2002-10-03	Eli Lilly And Company	Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques
US7671047B2 (en) *	2002-06-19	2010-03-02	Sanofi-Aventis Deutschland Gmbh	Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
JP2004131497A (ja) *	2002-09-18	2004-04-30	Satoshi Shuto	シスシクロプロパン誘導体
JP4680903B2 (ja) *	2003-07-29	2011-05-11	ハイ・ポイント・ファーマスーティカルズ、エルエルシー	ピリダジニル−ピペラジンおよびそれらのヒスタミンｈ３受容体リガンドとしての使用
EP1669350B1 (fr) *	2003-09-22	2012-02-29	Msd K.K.	Derives de piperidine
WO2005080361A1 (fr)	2004-02-02	2005-09-01	Pfizer Products Inc.	Modulateurs du recepteur de l'histamine-3
EP1735278B1 (fr) *	2004-04-01	2010-01-06	Eli Lilly And Company	Agents recepteurs de l'histamine h3, preparation et utilisations therapeutiques
US7456164B2 (en) *	2004-05-07	2008-11-25	Pfizer, Inc	3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (fr) *	2004-05-12	2005-11-16	Pfizer Limited	Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
JP2008543923A (ja)	2005-06-22	2008-12-04	ファイザー・プロダクツ・インク	ヒスタミン−３受容体アンタゴニスト
US8158673B2 (en) *	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
SI2124933T1 (sl) *	2007-01-22	2012-12-31	Pfizer Products Inc.	Tosilatna sol terapevtske spojine in farmacevtski sestavi tega

2006
- 2006-10-13 US US11/549,175 patent/US8158673B2/en not_active Expired - Fee Related
- 2006-10-16 EP EP06809114.9A patent/EP1951660B1/fr active Active
- 2006-10-16 RS RSP-2008/0173A patent/RS20080173A/sr unknown
- 2006-10-16 RS RS20140034A patent/RS53153B/sr unknown
- 2006-10-16 SI SI200631724T patent/SI1951660T1/sl unknown
- 2006-10-16 KR KR1020087009991A patent/KR101025358B1/ko not_active Expired - Fee Related
- 2006-10-16 GE GEAP200610660A patent/GEP20104937B/en unknown
- 2006-10-16 UA UAA200802656A patent/UA88719C2/ru unknown
- 2006-10-16 AU AU2006307645A patent/AU2006307645B2/en not_active Ceased
- 2006-10-16 EA EA200800946A patent/EA013602B1/ru not_active IP Right Cessation
- 2006-10-16 WO PCT/IB2006/002977 patent/WO2007049123A1/fr not_active Ceased
- 2006-10-16 BR BRPI0617797-2A patent/BRPI0617797A2/pt not_active IP Right Cessation
- 2006-10-16 JP JP2008537213A patent/JP4319245B2/ja not_active Expired - Fee Related
- 2006-10-16 CA CA2621323A patent/CA2621323C/fr not_active Expired - Fee Related
- 2006-10-16 PT PT68091149T patent/PT1951660E/pt unknown
- 2006-10-16 CN CN2006800399763A patent/CN101296898B/zh not_active Expired - Fee Related
- 2006-10-16 ES ES06809114.9T patent/ES2444370T3/es active Active
- 2006-10-16 DK DK06809114.9T patent/DK1951660T3/da active
- 2006-10-16 HR HRP20140061TT patent/HRP20140061T1/hr unknown
- 2006-10-16 AP AP2008004401A patent/AP2403A/xx active
- 2006-10-16 NZ NZ566488A patent/NZ566488A/en not_active IP Right Cessation
- 2006-10-16 PL PL06809114T patent/PL1951660T3/pl unknown
- 2006-10-20 NL NL1032713A patent/NL1032713C2/nl not_active IP Right Cessation
- 2006-10-24 PE PE2006001288A patent/PE20070720A1/es not_active Application Discontinuation
- 2006-10-25 GT GT200600471A patent/GT200600471A/es unknown
- 2006-10-25 UY UY29882A patent/UY29882A1/es not_active Application Discontinuation
- 2006-10-25 AR ARP060104658A patent/AR056879A1/es active IP Right Grant
- 2006-10-26 HN HN2006036385A patent/HN2006036385A/es unknown
- 2006-10-26 TW TW095139560A patent/TWI318206B/zh not_active IP Right Cessation
- 2006-10-26 DO DO2006000239A patent/DOP2006000239A/es unknown
2008
- 2008-02-28 IL IL189866A patent/IL189866A/en not_active IP Right Cessation
- 2008-04-02 TN TNP2008000150A patent/TNSN08150A1/fr unknown
- 2008-04-09 ZA ZA200803130A patent/ZA200803130B/xx unknown
- 2008-04-15 EC EC2008008373A patent/ECSP088373A/es unknown
- 2008-04-23 CU CU20080069A patent/CU23806B7/es not_active IP Right Cessation
- 2008-04-23 CR CR9910A patent/CR9910A/es not_active Application Discontinuation
- 2008-04-24 MY MYPI20081265A patent/MY145001A/en unknown
- 2008-04-25 MA MA30879A patent/MA29888B1/fr unknown
- 2008-04-28 NI NI200800132A patent/NI200800132A/es unknown
- 2008-05-16 NO NO20082264A patent/NO20082264L/no not_active Application Discontinuation
2009
- 2009-03-10 JP JP2009055839A patent/JP5064427B2/ja not_active Expired - Fee Related
2012
- 2012-03-09 US US13/415,944 patent/US8389743B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MY145001A (en)	2011-12-15
NI200800132A (es)	2010-02-15
US20080096955A1 (en)	2008-04-24
DOP2006000239A (es)	2007-04-30
KR20080054413A (ko)	2008-06-17
UY29882A1 (es)	2007-05-31
JP2009513619A (ja)	2009-04-02
TWI318206B (en)	2009-12-11
RS20080173A (sr)	2009-07-15
CA2621323C (fr)	2010-08-24
CN101296898A (zh)	2008-10-29
RS53153B (sr)	2014-06-30
AP2403A (en)	2012-05-04
MA29888B1 (fr)	2008-10-03
JP2009161554A (ja)	2009-07-23
WO2007049123A1 (fr)	2007-05-03
NZ566488A (en)	2011-07-29
NL1032713C2 (nl)	2007-10-09
JP4319245B2 (ja)	2009-08-26
TNSN08150A1 (fr)	2009-10-30
PE20070720A1 (es)	2007-08-11
KR101025358B1 (ko)	2011-03-28
BRPI0617797A2 (pt)	2011-08-09
CR9910A (es)	2008-05-16
CA2621323A1 (fr)	2007-05-03
HRP20140061T1 (hr)	2014-02-14
SI1951660T1 (sl)	2014-02-28
HK1124831A1 (en)	2009-07-24
JP5064427B2 (ja)	2012-10-31
PL1951660T3 (pl)	2014-04-30
AU2006307645B2 (en)	2012-02-16
GEP20104937B (en)	2010-03-25
ES2444370T3 (es)	2014-02-24
AR056879A1 (es)	2007-10-31
NL1032713A1 (nl)	2007-05-01
AP2008004401A0 (en)	2008-04-30
TW200800886A (en)	2008-01-01
IL189866A0 (en)	2008-11-03
EP1951660A1 (fr)	2008-08-06
AU2006307645A1 (en)	2007-05-03
IL189866A (en)	2012-06-28
EA013602B1 (ru)	2010-06-30
ZA200803130B (en)	2009-01-28
GT200600471A (es)	2007-06-08
US8158673B2 (en)	2012-04-17
US20120220568A1 (en)	2012-08-30
ECSP088373A (es)	2008-05-30
CU23806B7 (es)	2012-04-15
CU20080069A7 (es)	2009-12-17
CN101296898B (zh)	2013-07-24
PT1951660E (pt)	2014-02-10
EA200800946A1 (ru)	2008-10-30
US8389743B2 (en)	2013-03-05
EP1951660B1 (fr)	2013-12-11
DK1951660T3 (da)	2014-01-27
UA88719C2 (ru)	2009-11-10
HN2006036385A (es)	2009-10-30

Publication	Publication Date	Title
NO20082264L (no)	2008-07-22	Histamin-3 reseptorantagonister
WO2007088450A3 (fr)	2007-10-25	Chromane antagoniste du récepteur h-3
WO2007105053A3 (fr)	2007-12-06	Tétralines en tant qu'antagonistes du récepteur h-3
WO2007063385A3 (fr)	2007-10-04	Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques
DE602006018301D1 (de)	2010-12-30	Histamin-3-rezeptorantagonisten
WO2007138431A3 (fr)	2008-05-22	Antagonistes de l'éther histamine-3 azabicyclique
MX2009007782A (es)	2009-07-31	Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma.
BRPI0513486A (pt)	2008-05-06	derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3
CN115154470B (zh)	2024-09-20	使用食欲素-2受体拮抗剂治疗抑郁症的方法
JP2009161554A5 (fr)	2009-10-08
BRPI0507374A (pt)	2007-07-10	moduladores do receptor de histamina-3
EA201100423A1 (ru)	2011-10-31	Новые бензамиды, их получение и их применение в качестве лекарственных средств
MA32898B1 (fr)	2011-12-01	Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
BRPI0513444A (pt)	2008-05-06	antagonistas do receptor da histamina 3
BRPI0510501A (pt)	2007-10-30	antagonistas do receptor 3 de histamina
JP2018501217A (ja)	2018-01-18	統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
EA201170352A1 (ru)	2011-08-30	Способы лечения расстройств цнс
ATE479433T1 (de)	2010-09-15	Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
BRPI0516079A (pt)	2008-08-19	antagonistas de receptor de histamina-3
WO2006024955A8 (fr)	2007-05-18	Antagonistes des recepteurs d'amine histamine-3 azabicycliques
BRPI0512567A (pt)	2008-03-25	compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
BRPI0816571A2 (pt)	2015-12-22	"composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6"
MX2010006162A (es)	2010-06-25	Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida.
CY1114789T1 (el)	2016-12-14	Ανταγωνιστες υποδοχεα ισταμινης-3
Louvet et al.	2012	Wake-promoting agents: Search for next generation modafinil: Part IV

Legal Events

Date	Code	Title	Description
2017-05-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application